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Background. Thrombelastography (TEG) and rotational thromboelastometry (ROTEM) are 
viscoelastic haemostatic assays (VHA) which exploit the elastic properties of clotting blood. 
The aim of this systematic review and meta-analysis was to evaluate the usefulness of these 
tests in bleeding patients outside the cardiac surgical setting.
Materials and methods. We searched the Cochrane Library, MEDLINE, EMBASE and 
SCOPUS. We also searched clinical trial registries for ongoing and unpublished studies, and 
checked reference lists to identify additional studies. 
Results. We found 4 randomised controlled trials (RCTs) that met our inclusion criteria with 
a total of 229 participants. The sample size was small (from 28 to 111 patients) and the follow-up 
periods very heterogenous (from 4 weeks to 3 years). Pooled data from the 3 trials reporting on 
mortality (199 participants) do not show any effect of the use of TEG on mortality as compared 
to standard monitoring (based on the average treatment effect from a fixed-effects model): Risk 
Ratio (RR) 0.71; 95% Confidence Interval (CI): 0.43 to 1.16. Likewise, the use of VHA does 
not reduce the need for red blood cells (mean difference –0.64; 95% CI: –1.51 to 0.23), platelet 
concentrates (mean difference –1.12; 95% CI: –3.25 to 1.02), and fresh frozen plasma (mean 
difference –0.91; 95% CI: –2.02 to 0.19) transfusion. The evidence on mortality and other 
outcomes was uncertain (very low-certainty evidence, down-graded due to risk of biases, 
imprecision, and inconsistency).
Conclusions. Overall, the certainty of the evidence provided by the trials was too low for us 
to be certain of the benefits and harms of viscoelastic haemostatic assay in non-cardiac surgical 
settings. More, larger, and better-designed RCTs should be carried out in this area.
Keywords: viscoelastic assay, TEG, ROTEM, bleeding, allogeneic blood transfusion.
Introduction
Viscoelastic testing was initially developed 70 years 
ago by Hartert to detect real-time changes in viscosity 
of blood during the clotting process1. More recently, 
with the aim of implementing the original technique, 
two computerized, commercially-available, automated 
systems have been developed: thromboelastography 
(TEG, Haemonetics, Braintree, MA, Unites States 
of America) and rotational thromboelastometry 
(ROTEM, Penthapharm, Basel, Switzerland)2-4. Both 
these viscoelastic haemostatic assays tests dynamically 
evaluate clot formation and fibrinolysis, by continuously 
measuring and graphically displaying the kinetics of 
all stages of clot formation (initiation, propagation, 
strength and dissolution). Technically, a pin suspended 
by a torsion wire is lowered into a cup filled with whole 
blood. Either the cup (TEG) or the pin (ROTEM) is 
alternately rotated clockwise or anti-clockwise. As the 
blood clots, strands of fibrin form between the cup and 
the pin transmitting the torque of the cup to the torsion 
wire. The torque is continuously recorded electronically 
and displayed as a graph2,3. 
In recent years, TEG and ROTEM have been used 
to evaluate global clotting function, and to monitor 
and guide haemostatic treatment and allogeneic blood 
transfusion requirements in a variety of conditions 
characterised by excessive bleeding, including major 
surgery, liver transplantation, obstetric haemorrhage 
and trauma5-16. Interestingly, the beneficial effect of 
fibrinogen itself, the use of which can be guided and 
monitored by these techniques, is still debated in some 
of the aforementioned clinical settings17,18. While the use 
© 
SIM
TI 
S
rvi
zi 
Srl
All rights reserved - For personal use only 
No other use without premission
2Franchini M et al
Blood Transfus DOI 10.2450/2018.0003-18
of these point-of-care systems in patients undergoing 
cardiovascular surgery has been extensively studied by 
several randomised controlled trials (RCTs) and their 
results summarised by many systematic reviews and 
meta-analyses5,8,12,19,20, there has been less experience 
in other clinical settings where the use of this patient 
blood management technique is not supported by high 
strength recommendations21-24.
Thus, the aim of this paper is to review, through 
a systematic analysis of the existing literature, the 
published RCTs on the use of TEG and ROTEM 
viscoelastic haemostatic assay (VHA) technologies in 
bleeding clinical situations outside the cardiac surgical 
setting. 
Materials and methods
This systematic review was conducted according 
to the recommended Preferred Reporting Items for 
Systematic Reviews and Meta-Analyses (PRISMA) 
checklist guidelines25.
Search methods 
A computer-assisted literature search of the 
MEDLINE (through PUBMED), EMBASE, SCOPUS 
and Cochrane Library electronic databases was 
performed to identify RCTs on the use of TEG and 
ROTEM in bleeding conditions. The following 
search strategy was used to maximise search 
specificity and sensitivity: "viscoelastic assays" 
AND "thromboelastography" AND "TEG" AND 
"rotational thromboelastometry" AND "ROTEM" 
AND "trauma" AND "bleeding" AND "surgery" AND 
"obstetric hemorrhage" AND "liver transplantation" 
AND "allogeneic blood transfusion". In addition, 
we hand-searched the reference lists of the most 
relevant items (original studies and reviews) in order 
to identify potentially eligible studies not captured 
by the initial literature search.
Study selection
Study selection was performed independently by two 
reviewers (MF and MC), with disagreements resolved 
through discussion and on the basis of the opinion of a 
third reviewer (CM). Eligibility assessment was based 
on the title or abstract and on the full text if required. 
Articles were eligible if they reported either in the title 
or in in the abstract the use of TEG and/or ROTEM 
in patients with bleeding conditions. Only RCTs 
published in full in English between January 1970 
and November 2017 were included in this systematic 
review and meta-analysis. RCTs evaluating the use 
of TEG/ROTEM in cardiovascular surgery were 
excluded from this analysis since they have been 
extensively reviewed elsewhere12,19,20.
Data extraction
For each study included in the systematic review, 
the following data were extracted by two reviewers 
(MF and MC) independently: sample size (TEG/
ROTEM and control groups), inclusion criteria, type 
of intervention, follow up, blood loss, need for blood 
transfusion and amount of blood products transfused, 
mortality, complications and adverse events. The longest 
follow-up period for each trial was also recorded when 
available. Disagreement was resolved by consensus and 
by the opinion of a third reviewer (CM) if necessary.
Outcome measures
The monitoring by VHA during surgical or other 
invasive procedures was evaluated as a therapeutic 
treatment possibly producing beneficial effects 
in haemorrhage-prone patients. The efficacy was 
evaluated as all-causes mortality reduction (primary 
outcome). Moreover, the sparing effect regarding the 
administration of blood products (red blood cells, 
platelet concentrates and fresh frozen plasma) was also 
accounted for (secondary outcome). 
Assessment of risk of bias in included studies
Two review authors (MF, MC) independently 
assessed the risk of bias of each included study following 
the domain-based evaluation described in the Cochrane 
Handbook for Systematic Reviews of Interventions26. 
They discussed any discrepancies and achieved 
consensus on the final assessment. The Cochrane "Risk 
of bias" tool addresses six specific domains: sequence 
generation, allocation concealment, blinding, incomplete 
data, selective outcome reporting, and other issues 
relating to bias. We have presented our assessment of 
risk of bias using two "Risk of bias" summary figures: 
1) a summary of bias for each item across all studies; 
and 2) a cross-tabulation of each trial according to all 
the "Risk of bias" items. 
"Summary of findings" tables
We used the principles of the GRADE system to 
assess the quality of the body of evidence associated 
with specific outcomes, and constructed a "Summary 
of findings" table using REVMAN 527. These tables 
present key information concerning the certainty 
of the evidence, the magnitude of the effects of the 
interventions examined, and the sum of available data for 
the main outcomes28. The "Summary of findings" tables 
also includes an overall grading of the evidence related to 
each of the main outcomes using the GRADE approach, 
which defines the certainty of a body of evidence as the 
extent to which one can be confident that an estimate 
of effect or association is close to the true quantity of 
specific interest (Online Supplementary Table SI). The 
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certainty of a body of evidence involves consideration 
of within-trial risk of bias (methodological quality), 
directness of evidence, heterogeneity, precision of 
effect estimates, and risk of publication bias29. We have 
presented the following outcomes in the "Summary of 
findings" tables: i) mortality; ii) transfusion of red blood 
cells; iii) transfusion of platelet concentrates; and iv) 
transfusion of fresh frozen plasma.
When evaluating the "Risk of bias" domain, we 
down-graded the GRADE assessment only when we 
classified a study as being at high risk of bias for one 
or more of the following domains: selection, attrition, 
reporting, and other bias; or when the "Risk of bias" 
assessment for selection bias was unclear (this was 
classified as unclear for either the generation of the 
randomisation sequence or the allocation concealment 
domain). We did not down-grade for high risk of 
bias in performance and detection domains, since we 
judged that the outcomes considered are not likely to be 
influenced by lack of blinding, and for unclear "Risk of 
bias" assessments in other domains. 
Statistical evaluation and meta-analysis
The primary outcome was mortality, evaluated 
through meta-analytical pooling as the Risk Ratio 
(RR) between VHA monitoring (treatment group) vs 
standard of care (control group). Secondary outcomes 
were related to blood product use, including red blood 
cells (RBC), platelet concentrates (PC), and fresh frozen 
plasma (FFP) transfusion. For the secondary outcomes, 
the main index under evaluation through meta-analytical 
pooling was the unstandardised weighted mean 
difference (WMD) between VHA monitoring (treatment 
group) vs standard of care (control group). 
In meta-analysis of continuous outcomes, the sample 
size, mean, and standard deviation are required from 
included studies. Some trial studies only report the 
median, the minimum and maximum values (range), 
and/or the first and third quartiles (interquartile range). 
When results concerning quantitative outcomes are 
provided as medians and range, or interquartile interval, 
pooling them with studies reporting means and standard 
deviations is problematic. Methods are available in the 
literature to convert medians and ranges to means and 
standard deviations. The best known are those by Hozo 
and Colleagues30 and by Wan and Colleagues31. In the 
present meta-analysis, we used the method of Hozo and 
Colleagues, which is more reliable for small size studies. 
We used a random-effects model as default approach 
for undertaking a meta-analysis. A fixed-effect approach 
was used only when clinical heterogeneity was 
considered minimal and statistical heterogeneity was 
not statistically significant for the ² value and 0% for 
the I² measure32.
In addition, the power for a prospective extension 
of the meta-analytic accumulation of evidence 
was investigated for the mortality outcome by the 
conventional approach, assuming a hypothetical, 
provisional guess (based on the actual data) of risk 
as 21% for TEG-monitored patients, and as 30% for 
control patients. 
For statistical calculations and bias assessment, we 
used Cochrane Review Manager 5 software and Stata 
15.1. Moreover, the same task was also viewed as an 
evolving prospective meta-analysis and graphically 
depicted by trial sequential analysis (TSA) with the use 
of TSA software33,34.
Results
In total, 4,524 articles were initially identified 
after the initial electronic and manual search, which 
was concluded on 30th November 2017 (Figure 1). Of 
these, 4,472 were excluded because they focused on 
other topics. Thus, 52 potentially relevant articles were 
selected and the next screening led to the exclusion of 
48 additional studies (reviews, protocols of RCTs, cohort 
studies, duplicates, studies containing no informative 
data). The remaining four randomised studies35-38 were 
included in the systematic review and meta-analysis 
(see Table I for main characteristics and results of the 
included studies). Overall, 229 patients (114 undergoing 
viscoelastic tests and 115 controls) were enrolled in 
the four RCTs selected for the meta-analysis. Of these, 
three trials reported mortality as outcome, with different 
follow-up times (28 days, 90 days and 3 years). 
Risk of bias in included studies
We assessed no study as being at low risk of bias. All 
the four included studies were at high risk of bias for one 
or more domains, and three studies were at unclear risk 
of bias for three domains (Figures 2 and 3).
Allocation
We assessed one study as being at high risk of 
selection bias, as randomisation was by weekly 
alternation of the two treatments, so the intervention 
allocations could have been foreseen in advance37. The 
reports on random sequence generation and allocation 
concealment in the remaining studies were unclear.
Blinding
All the studies were open label, and were graded 
as high risk of performance bias (blinding of 
participants and personnel). The study by Gonzalez 
et al.37 was graded at low risk of detection bias, since 
outcome assessors had access to the text assigned 
to the study group and were blinded to the other 
tests, and because an independent data and safety 
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Table I - Characteristics and main results of the 4 RCTs on the use of TEG/ROTEM in bleeding patients included in the 
meta-analysis.
First 
author, 
yearref.
VHA 
group/
control 
group 
Inclusion criteria Interventions Follow-up Outcomes
Mortality1 Blood loss
mL2 
Transfusions
units2
Complications/ 
AEs
Wang,
201035
14/14 Patients undergoing 
OLT
IG: monitoring during 
surgery using TEG 
assay
CG: monitoring 
using conventional 
coagulation assays
3 years IG: 2/14 (14.3)
CG: 3/14 (21.4)
IG: 4775.7 
(4264.7) 
CG: 6348.0 
(3704.1)
IG: RBC 14.2 (7.1)
PC 27.3 (13.9)
FFP 12.8 (7.0)
CG: RBC 16.7 (12.8)
PC 30.1 (18.5)
FFP 21.5 (12.7) 
NR
Schaden,
201236
14/16 Surgical excision 
of burn wounds 
performed on the 
third day after burn 
trauma
IG: monitoring using 
ROTEM assay
CG: coagulation 
management according 
to clinician's judgment 
Until 
discharge 
from ICU
NR NR IG: RBC 3.1 (2.1)
PC 0
FFP 0
CG: RBC 4.8 (3.0)
PC 0.2 (0-2)3
 FFP 5.0 (1.5-7.5)3
NR
Gonzalez,
201637
56/55 Injured adult 
patients
IG: monitoring using 
TEG assay
CG: monitoring 
using conventional 
coagulation assays
28 days IG: 11/56 (19.6)
CG: 20/55 (36.4) 
NR IG: RBC 9.5 (5-16)3
PC 1.0 (0-2)3
FFP 5.0 (3-9)3
CG: RBC 11.0 
(6-16)3
PC 1.0 (0-2)3
 FFP 6.0 (4-9)3
NR
De Pietri,
201638
30/30 Patients with 
cirrhosis and severe 
coagulopathy 
undergoing invasive 
procedures
IG: monitoring using 
TEG assay
CG: standard of care
90 days IG: 8/30 (26.6)
CG: 7/30 (23.3)
NR IG: RBC 0.2 (0-2)3
PC 0.9 (0-6)3
FFP 0.7 (0-10)3
CG: RBC 0.3 (0-2)3
PC 3.5 (0-10)3
FFP 4.4 (0-6)3
1 post-procedure 
bleeding event 
in CG
VHA: viscoelastic hemostatic assay; AEs: adverse events; OLT: orthotopic liver transplantation; IG: intervention group; CG: control group; TEG: thromboelastography; 
ROTEM: rotational thromboelastometry; ICU: intensive care unit; RBC: red blood cells; PC: platelet concentrates; FFP: fresh frozen plasma; NR: not reported. 1Number 
(%); 2Mean (standard deviation); 3Median (range).
Figure 1 - Flow chart of the inclusion of the studies.
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Figure 2 -  Risk of bias. A review of Authors' judgements about each risk of bias item presented 
as percentages across all included studies.
Figure 3 -  Risk of bias summary. A review Authors' judgements about each risk of bias item 
for each included study.
monitoring board oversaw the conduct of the trial 
and reviewed any suspected adverse events; the 
remaining three studies were graded at unclear risk of 
detection bias due to the fact that they did not provide 
information to permit judgement about "high" or 
"low" risk of bias35,36,38.
Incomplete outcome data
One study was judged at high risk of attrition bias 
because three patients randomised in the experimental 
group could not receive the assigned treatment, and 
were switched and treated as controls30. The remaining 
studies were judged at low risk of bias.
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Selective reporting
Selective reporting was low in all included studies. 
Other potential sources of bias
We judged at high risk of other source of bias one 
study performed in cirrhotic patients with coagulopathy, 
which excluded subjects most likely to suffer from 
alterations of coagulation (e.g., with suspected infections 
or sepsis), making the sample obtained not representative 
of the entire population intended to be analysed38.
Effects of interventions
The effect of the intervention (VHA monitoring) on 
mortality (primary outcome) was assessed on three trials, 
all using TEG monitoring, reporting on this outcome. 
The overall mortality was 21% on treated patients (21 out 
of 100) and 30.3% in the control group (30 out of 99).
Using the average treatment effect from a 
fixed-effects model, the use of TEG does not 
reduce mortality when compared to the control 
group: three trials, 199 patients; RR 0.71, 95% CI: 
0.44  to 1.15; p for overall effect=0.16; I²=0% (Figure 4). 
As far as the secondary outcomes is concerned, the 
use of VHA does not reduce the need for red blood 
cells (4 trials, 229 patients; mean difference –0.64, 95% 
CI: –1.51 to 0.23; p for overall effect=0.15; I²=52%), 
for platelet concentrates (3 trials, 199 patients; mean 
difference –1.12, 95% CI: –3.25 to 1.02; p for overall 
effect=0.31; I²=87%), as well as for fresh frozen plasma 
transfusions (3 trials, 199 patients; mean difference 
–0.91, 95% CI: –2.02 to 0.19; p for overall effect=0.11; 
I²=52%) (Figure 5). Based on GRADE assessment, all 
these comparisons were graded as very low certainty 
evidence, and down-graded once because of imprecision 
Figure 4 - Forest plot of comparison. Thromboelastography vs standard laboratory measures, outcome and 
mortality.
Figure 5 - Forest plots of comparison. Thromboelastography vs standard laboratory measures, secondary 
outcomes: (A) red blood cell transfusion, (B) platelet concentrate transfusion, and (C) fresh 
frozen plasma transfusion.
A
B
C
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(due to small sample size), once because of inconsistency 
(I²=52-87 %), and twice because of the risk of biases 
(see summary of findings in Table II, and funnel plots in 
Figures 2 and 3). Online Supplementary Content Figure 
S1 reports the TSA, i.e., the additional observations to 
reach a 50% power (n=362) and an 80% power (n=734). 
Actually, the available number is much lower, 199 (55% 
and 27%, respectively). 
Discussion
Thrombelastography and ROTEM are point-of-care 
systems able to capture the dynamic nature of clotting. 
Table II -  Thromboelastography (TEG) compared with standard laboratory measures for patients with coagulopathy in 
non-cardiac surgical settings. Summary of findings table.
Outcomes Illustrative comparative risks* 
(95%CI)
Relative effect
(95%CI)
N. of participants
(studies)
Quality of the 
evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Standard lab 
measures
TEG
Mortality 30 per 100 21 per 100
(12.9 to 34.8 )
RR 0.71
(0.43 to 1.16)
199 
(3 studies)
⊕⊝⊝⊝
very low1
On average, it is unclear 
whether or not use of 
TEG compared with 
standard laboratory 
measures
reduces mortality over a
follow-up period ranging 
from 28 days to 3 years.
Red blood cell 
transfusion
804 units per 
100 pts
740 units per 100 pts 
(653 to 827) 
Mean difference :
–0.64
(–1.51 to 0.23)
4 studies
(229 patients)
⊕⊝⊝⊝
very low2
On average, it is unclear 
whether or not use of 
TEG compared with 
standard laboratory 
measures
reduces the need for red 
blood cell transfusion
Platelet concentrate 
transfusion
587 units per 
100 pts
475 Units per 100 pts 
(262 to 689)
Mean difference :
–1.12
(–3.25 to 1.02) 
3 studies
(199 pts)
⊕⊝⊝⊝
very low2
On average, it is unclear 
whether or not use of 
TEG compared with 
standard laboratory 
measures
reduces the need for 
platelet concentrate 
transfusion
Fresh frozen plasma 771 units per 
100 patients
680 Units per 100 pts 
(569 to 790)
Mean difference:
 –0.91
(–2.02 to 0.19) 
3 studies
(199 pts)
⊕⊝⊝⊝
very low2
On average, it is unclear 
whether or not use of 
TEG compared with 
standard laboratory 
measures reduces the 
need for fresh frozen 
plasma transfusion
Patient population: patients with coagulopathy; Settings: inpatients; Intervention: thromboelastography; Comparison: standard laboratory measures of 
blood coagulation.
*The assumed risk is the mean control group risk across studies. The corresponding risk (and its 95% confidence interval [CI]) is based on the assumed risk 
in the comparison group and the relative effect of the intervention (and its 95%CI). RR: Risk Ratio; pts: patients.
GRADE Working Group grades of evidence. High quality: Further research is very unlikely to change our confidence in the estimate of effect. Moderate 
quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate. Low quality: Further 
research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.
1Down-graded once for risk of bias due to 1 study (with the highest weighting in the meta-analysis) being at high risk of selection bias, and 3 studies being at 
unclear risk of selection bias. Down-graded once due to the design of one study in cirrhotic patients with coagulopathy, which excluded subjects most likely 
suffering from alterations of coagulation (e.g., with suspected infections or sepsis), making the sample obtained not representative of the population intended 
to be analysed. Down-graded once for imprecision due to small sample size. 2Down-graded twice for risk of biases; down-graded once for imprecision; 
down-graded once for inconsistency due to the heterogeneity (I2 52-87 %).
The information provided by these VHA has been 
used in recent years to create targeted, individualised 
treatment algorithms with the aim of improving 
outcome of patients with excessive bleeding4. A number 
of clinical trials have been performed in this field, 
mostly in the cardiac surgical setting, and an up-dated 
systematic review and meta-analysis of these was 
recently published by Serraino and Murphy12. After 
the analysis of 15 RCTs involving 8,737 participants, 
the Authors concluded that, although the use of TEG 
or ROTEM resulted in a reduction in the frequency of 
RBC and platelet transfusions, this did not have any 
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effect on mortality when compared with standard care. 
In order to assess the impact of viscoelastic blood tests 
in other bleeding settings, we performed a systematic 
review and meta-analysis of the existing literature. 
Only 4 RCTs were identified after a systematic search, 
covering various clinical areas (1 liver transplantation, 
1 surgery in bleeding burn patients, 1 trauma-induced 
coagulopathy, and 1 invasive procedures in patients with 
severe coagulopathy associated with liver cirrhosis)35-38.
After a pooled analysis of the results from the studies, 
we found that the use of TEG does not reduce mortality 
when compared with the control group: RR 0.71, 95% 
CI: 0.44 to 1.15. 
The level of evidence according to the GRADE 
method was of very low quality, since the trials were at 
high risk of selection biases and imprecision due to the 
small sample size. 
Likewise, the use of VHA as compared with standard 
laboratory measures does not reduce the need for RBC 
(mean difference, –0.64; 95% CI: –1.51 to 0.23), platelet 
concentrate (mean difference, –1.12; 95% CI: –3.25 
to 1.02), and fresh frozen plasma transfusion (mean 
difference, –0.91; 95 % CI: –2.02 to 0.19). For all 
these outcomes, the level of the evidence was graded 
at very low quality due to risk of bias, imprecision and 
inconsistency, with a substantial degree of heterogeneity 
(Table II). One of the limits of our analysis relates to 
the approximate methods employed to obtain means 
and standard deviations from medians and ranges that 
add uncertainty to these evaluations. These methods 
are approximate, and give the best results when the true 
data distribution is normal or near normal. In our meta-
analysis, the accuracy of the evaluation was necessarily 
indeterminate, since we have no indication of the real 
distribution of the continuous variables. 
In conclusion, the available evidence does not allow 
any conclusions to be drawn as to whether the use of 
VHA offers a significant benefit regarding important 
clinical end points (mortality and transfusion needs) as 
compared to standard monitoring in bleeding patients 
outside the cardiac surgical setting. More, larger, and 
better designed randomised controlled trials should be 
carried out in this area in order to better clarify the exact 
role of VHA in the management of acquired bleeding 
conditions. 
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Table SI - GRADE ratings and their interpretation symbol. 
GRADE 
symbols
Quality Interpretation 
⊕⊕⊕⊕ High We are very confident that the true effect lies close to that of the estimate of the effect. 
⊕⊕⊕Ο Moderate We are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there 
is a possibility that it is substantially different. 
⊕⊕ΟΟ Low Our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect. 
⊕ΟΟΟ Very low We have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate 
of effect. 
Table taken from the GRADE Handbook, available from: http://gdt.guidelinedevelopment.org/app/handbook/handbook.html#h.9rdbelsnu4iy.
Figure S1 - Trial sequential analysis. The process of evidence accumulation is quantified as cumulative z-score (blue line). 
The x-axis reports the number of enrolled patients (sample axis). The y-axis spans the evidence against the null 
hypothesis, as Z-score. The horizontal brown lines indicate the limits of 5% significance according to the conventional 
method (without any penalisation). Bent lines of alpha error and beta error depict funnels, establishing a penalty 
for the initial, underpowered meta-analysis. (The alpha curves are actually over the horizontal brown line; the beta 
curves are underneath). Vertical lines indicate the number of enrolled patients for a power of 50% and 80%. The 
final objective is to assess the development of the investigation, which eventually could cross the alpha boundaries, 
thus endorsing the alternative hypothesis, or persisting in a low level, thus ending crossing the beta boundaries of 
futility; the latter possibility would suggest the practical failure to demonstrate the experimental hypothesis.
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